Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;593(7857):130-135.
doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang #  1 , Manoj S Nair #  1 , Lihong Liu #  1 , Sho Iketani #  1   2 , Yang Luo  1 , Yicheng Guo  1 , Maple Wang  1 , Jian Yu  1 , Baoshan Zhang  3 , Peter D Kwong  3   4 , Barney S Graham  3 , John R Mascola  3 , Jennifer Y Chang  1   5 , Michael T Yin  1   5 , Magdalena Sobieszczyk  1   5 , Christos A Kyratsous  6 , Lawrence Shapiro  1   4   7 , Zizhang Sheng  1 , Yaoxing Huang  8 , David D Ho  9   10   11
Affiliations

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al. Nature. 2021 May.

Abstract

The COVID-19 pandemic has had widespread effects across the globe, and its causative agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to end this pandemic. Single and combination therapies with monoclonal antibodies have received emergency use authorization1-3, and more treatments are under development4-7. Furthermore, multiple vaccine constructs have shown promise8, including two that have an approximately 95% protective efficacy against COVID-199,10. However, these interventions were directed against the initial SARS-CoV-2 virus that emerged in 2019. The recent detection of SARS-CoV-2 variants B.1.1.7 in the UK11 and B.1.351 in South Africa12 is of concern because of their purported ease of transmission and extensive mutations in the spike protein. Here we show that B.1.1.7 is refractory to neutralization by most monoclonal antibodies against the N-terminal domain of the spike protein and is relatively resistant to a few monoclonal antibodies against the receptor-binding domain. It is not more resistant to plasma from individuals who have recovered from COVID-19 or sera from individuals who have been vaccinated against SARS-CoV-2. The B.1.351 variant is not only refractory to neutralization by most monoclonal antibodies against the N-terminal domain but also by multiple individual monoclonal antibodies against the receptor-binding motif of the receptor-binding domain, which is mostly due to a mutation causing an E484K substitution. Moreover, compared to wild-type SARS-CoV-2, B.1.351 is markedly more resistant to neutralization by convalescent plasma (9.4-fold) and sera from individuals who have been vaccinated (10.3-12.4-fold). B.1.351 and emergent variants13,14 with similar mutations in the spike protein present new challenges for monoclonal antibody therapies and threaten the protective efficacy of current vaccines.

PubMed Disclaimer

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. N. Engl. J. Med. 384, 229–237 (2021). - DOI - PubMed
    1. Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010–1014 (2020). - DOI - PubMed - PMC
    1. Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. J. Am. Med. Assoc. 325, 632–644 (2021). - DOI
    1. Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115–119 (2020). - DOI - PubMed
    1. Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020). - DOI - PubMed

Publication types

MeSH terms